Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 for Polycythemia Vera
NCT04182100Phase 2Completed
- Sponsor
- PharmaEssentia
- Start
- Dec 2019
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Primary endpoint: Proportion of Subjects Who Achieved Durable Phlebotomy-free Complete Hematological Response (CHR) at 12 months. Started Dec 2019; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04182100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182100.